计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| H647174-5mg |
5mg |
期货 ![]() |
| |
| H647174-10mg |
10mg |
期货 ![]() |
| |
| H647174-50mg |
50mg |
期货 ![]() |
| |
| H647174-100mg |
100mg |
期货 ![]() |
|
| 别名 | HDAC/mTOR 抑制剂 1 |
|---|---|
| 规格或纯度 | ≥98% |
| 英文名称 | HDACs/mTOR Inhibitor 1 |
| 生化机理 | HDACs/mTOR 抑制剂 1 是一种 HDACs 和 mTOR 双重抑制剂,对 HDAC1、HDAC6 和 mTOR 的 IC 50 s 分别为 0.19 nM、1.8 nM 和 1.2 nM。HDACs/mTOR 抑制剂 1 能刺激细胞周期停滞在 G0/G1 期,并诱导肿瘤细胞凋亡,毒性较低。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC 50 s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1 , HDAC6 , mTOR , respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo . HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies In Vitro HDACs/mTOR Inhibitor 1 (Compound 12l) inhibits leukemia cells proliferation with IC 50 s of 4.05, 9.01, 9.98 μM for MV4-11, OCI-AML2, OCI-AML3 cells. HDACs/mTOR Inhibitor 1 (0-10 μM, 6 h or 24 h) downregulates p-ERK and increases Ac-H3 in MV4-11 cells. HDACs/mTOR Inhibitor 1 (10 to 1000 nM, 48 h) reduces S-phase cells and increases the percentage of cells in G0/G1 phase in MV4-11 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MV4-11 cells Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 6 h or 24 h Result: Downregulated p-ERK (24 h) and increased of the Ac-H3 (6 h) in a dose-dependent manner. In Vivo HDACs/mTOR Inhibitor 1 (Compound 12l) (10 or 20 mg/kg, i.v.) inhibits tumor growth without significant toxicity in MV4-11 and MM1S xenograft NOD/SCID mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MV4-11 xenograft NOD/SCID mouse model Dosage: 10 mg/kg Administration: Intravenous injection (i.v.), every two days (Q2D)×6 Result: The TGI (tumor growth inhibitory rate) was 53.1%. Form:Solid IC50& Target:HDAC1 0.19 nM (IC 50 ) HDAC6 1.8 nM (IC 50 ) mTOR 1.2 nM (IC 50 ) |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 未知 |
|---|---|
| IIUPAC Name | (2R)-N-[4-[1-[7-(hydroxyamino)-7-oxoheptyl]-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-methylmorpholine-4-carboxamide |
| INCHI | 1S/C28H38N8O5/c1-20-19-35(14-17-41-20)28(38)30-22-9-7-21(8-10-22)25-31-26(34-12-15-40-16-13-34)23-18-29-36(27(23)32-25)11-5-3-2-4-6-24(37)33-39/h7-10,18,20,39H,2-6,11-17,19H2,1H3,(H,30,38)(H,33,37)/t20-/m1/s1 |
| InChi Key | YPXRCUVTZDXVHY-HXUWFJFHSA-N |
| Smiles | CC1CN(CCO1)C(=O)NC2=CC=C(C=C2)C3=NC4=C(C=NN4CCCCCCC(=O)NO)C(=N3)N5CCOCC5 |
| Isomeric SMILES | C[C@@H]1CN(CCO1)C(=O)NC2=CC=C(C=C2)C3=NC4=C(C=NN4CCCCCCC(=O)NO)C(=N3)N5CCOCC5 |
| PubChem CID | 137628684 |
| 分子量 | 566.65 |
| 溶解性 | DMSO : 32.5 mg/mL (57.35 mM; Need ultrasonic) |
|---|